26th May 2005 07:01
BTG PLC26 May 2005 BTG plc appoints Christine Soden as Chief Financial Officer London, UK, 26 May 2005: BTG plc (LSE: BGC), the medical innovations company,announces the appointment of Christine Helen Soden as Chief Financial Officer.The appointment will take effect from 1 July 2005. Christine joins BTG from Oxagen Limited, a privately owned drug discoverycompany, to which she was appointed Chief Financial Officer in 2000. Withresponsibility for the finance, IT, legal and operations functions, Christinehelped refinance and restructure Oxagen. From 1996 until 1999, Christine was Finance Director of Chiroscience Group plcthen Chief Financial Officer of Celltech Chiroscience plc following the mergerof the two companies. During this period she played a major role infundraising, company acquisition, securing six partnerships for drug developmentprogrammes, building a part of the business for subsequent sale, and corporatedevelopment, leading to the merger. Prior to this, Christine spent over four years as Group Financial Controller andHead of Tax and Treasury at Medeva plc, where she was involved in acquisitions,financing and co-ordinating its US stockmarket listing. Christine, aged 47, has degree in mathematics from Durham University. Aftergraduating she qualified as a chartered account and worked for accountancy firmsClark Whitehill and Price Waterhouse. She then spent eight years in a number offinance roles with investment group Pavion International plc and Stringer Saulsolicitors. Sir Brian Fender, Chairman of BTG, commented: "We are delighted Christine isjoining BTG. She is a commercially focused Chief Financial Officer, withsignificant public company experience in the biotechnology and pharmaceuticalindustries. We look forward to working with her as we implement our strategyand further develop the business." Christine succeeds Rusi Kathoke, BTG's Chief Financial Officer since 1986, whoretires in July. Christine Soden is senior Non-executive Director of Provalis plc, where she alsochairs the Audit Committee. There are no other details to be disclosedconcerning Christine in relation to paragraphs 16.4(a) and 16.4(b) of theFinancial Services Authority Listing Rules. For further information contact: BTG Financial DynamicsAndy Burrows, Director of Investor Relations Ben Atwell+44 207 575 1741 +44 207 831 3113 About BTG BTG acquires rights to early stage pharmaceuticals and other medicaltechnologies from a global network of corporations, research institutions anduniversities. We apply resources including finance, intellectual property andproject management skills to fund and manage outsourced preclinical and clinicaldevelopment programmes. We then commercialise the technologies by licensing topharmaceutical companies, or by creating companies to exploit them. Ourpipeline comprises around 50 assets at varying stages of development,contributing to an increasing range of products marketed by our licensees. BTGoperates from London, Philadelphia and Tokyo. For further information visit ourwebsite at www.btgplc.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
BTG